These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
194 related items for PubMed ID: 20088008
1. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. Jeremias A, Vasu S, Gruberg L, Kastrati A, Stone GW, Brown DL. Catheter Cardiovasc Interv; 2010 May 01; 75(6):895-902. PubMed ID: 20088008 [Abstract] [Full Text] [Related]
2. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ. JAMA; 2005 Apr 13; 293(14):1759-65. PubMed ID: 15827315 [Abstract] [Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P, ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. N Engl J Med; 2001 Jun 21; 344(25):1895-903. PubMed ID: 11419426 [Abstract] [Full Text] [Related]
6. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW, CADILLAC Investigators. Circulation; 2003 Sep 16; 108(11):1316-23. PubMed ID: 12939213 [Abstract] [Full Text] [Related]
7. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, Neumann FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA. Am Heart J; 2004 Mar 16; 147(3):457-62. PubMed ID: 14999194 [Abstract] [Full Text] [Related]
12. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De Luca G. Platelets; 2012 Mar 16; 23(4):274-81. PubMed ID: 21988317 [Abstract] [Full Text] [Related]
13. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials. de Queiroz Fernandes Araújo JO, Veloso HH, Braga De Paiva JM, Filho MW, Vincenzo De Paola AA. Am Heart J; 2004 Dec 16; 148(6):937-43. PubMed ID: 15632875 [Abstract] [Full Text] [Related]
17. Stenting and abciximab in primary angioplasty: a review of current status. De Luca G, Suryapranata H, Piscione F, Barbato E, Chiariello M. Ital Heart J; 2005 Nov 16; 6(11):874-80. PubMed ID: 16320920 [Abstract] [Full Text] [Related]